These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 23952246)

  • 1. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
    Xicoy B; Jiménez MJ; García O; Bargay J; Martínez-Robles V; Brunet S; Arilla MJ; Pérez de Oteyza J; Andreu R; Casaño FJ; Cervero CJ; Bailén A; Díez M; González B; Vicente AI; Pedro C; Bernal T; Luño E; Cedena MT; Palomera L; Simiele A; Calvo JM; Marco V; Gómez E; Gómez M; Gallardo D; Muñoz J; de Paz R; Grau J; Ribera JM; Benlloch LE; Sanz G
    Leuk Lymphoma; 2014 Jun; 55(6):1300-3. PubMed ID: 23952246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
    Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
    Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry.
    Grinblatt DL; Sekeres MA; Komrokji RS; Swern AS; Sullivan KA; Narang M
    Leuk Lymphoma; 2015 Apr; 56(4):887-95. PubMed ID: 24956145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
    Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
    Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
    Bernal T; Martínez-Camblor P; Sánchez-García J; de Paz R; Luño E; Nomdedeu B; Ardanaz MT; Pedro C; Amigo ML; Xicoy B; del Cañizo C; Tormo M; Bargay J; Valcárcel D; Brunet S; Benlloch L; Sanz G; ; ;
    Leukemia; 2015 Sep; 29(9):1875-81. PubMed ID: 25943181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
    Garcia-Manero G; Gore SD; Kambhampati S; Scott B; Tefferi A; Cogle CR; Edenfield WJ; Hetzer J; Kumar K; Laille E; Shi T; MacBeth KJ; Skikne B
    Leukemia; 2016 Apr; 30(4):889-96. PubMed ID: 26442612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
    Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
    Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
    Bouchla A; Thomopoulos TP; Papageorgiou SG; Apostolopoulou C; Loucari C; Mpazani E; Pappa V
    Epigenomics; 2021 Jul; 13(14):1129-1143. PubMed ID: 34291653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
    Papageorgiou SG; Kontos CK; Kotsianidis I; Vasilatou D; Symeonidis A; Galanopoulos A; Bouchla A; Hatzimichael E; Repousis P; Zikos P; Viniou NA; Poulakidas E; Vassilakopoulos TP; Diamantopoulos P; Diamantopoulos MA; Mparmparousi D; Bouronikou E; Papadaki H; Panayiotidis P; Pappa V
    Hematol Oncol; 2018 Oct; 36(4):693-700. PubMed ID: 30129144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
    Mozessohn L; Cheung MC; Fallahpour S; Gill T; Maloul A; Zhang L; Lau O; Buckstein R
    Br J Haematol; 2018 Jun; 181(6):803-815. PubMed ID: 29767427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
    Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.
    Laribi K; Bolle D; Alani M; Ghnaya H; Besançon A; Farhi J; Mheidly K; Denizon N; Baugier de Materre A
    Cancer Med; 2019 May; 8(5):2188-2195. PubMed ID: 30993891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.